Altimmune Inc logo

Altimmune Inc

$ 12.47 +0.1 (+0.81%) 11:30 AM EST
P/E:
At Loss
P/B:
2.97
Market Cap:
$ 611.35M
Enterprise V:
$ 423.02M
Volume:
264.34K
Avg Vol (2M):
3.03M
Also Trade In:
Volume:
264.34K
Market Cap $:
611.35M
PE Ratio:
At Loss
Avg Vol (2-Month):
3.03M
Enterprise Value $:
423.02M
PB Ratio:
2.97
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH (non-alcoholic steatohepatitis). In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B virus (HBV).
Name Current Vs Industry Vs History
Cash-To-Debt 138.39
Equity-to-Asset 0.93
Debt-to-Equity 0.01
Debt-to-EBITDA -0.01
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 20.99
Distress
Grey
Safe
Beneish M-Score -3.85
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 21.47
9-Day RSI 27.07
14-Day RSI 33.95
6-1 Month Momentum % 168.27
12-1 Month Momentum % 19.37

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 14.12
Quick Ratio 14.12
Cash Ratio 13.34
Days Sales Outstanding 143.94

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -65.3

Financials (Next Earnings Date:2022-11-10 Est.)

ALT's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:ALT

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Embed

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 3.476
EPS (TTM) ($) -2.24
Beta -0.7
Volatility % 165.65
14-Day RSI 33.95
14-Day ATR ($) 1.941705
20-Day SMA ($) 17.569
12-1 Month Momentum % 19.37
52-Week Range ($) 3.83 - 23.49
Shares Outstanding (Mil) 49.03

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Altimmune Inc Filings

Document Form Filing Date
No Filing Data

Altimmune Inc Analysis

Share your research

Headlines

See More
No news.